DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced consolidated results for the first quarter of 2011. First quarter 2011 revenues were $2.8 million compared with $2.7 million reported for the first quarter of 2010. Gross profit for the first quarter of 2011 was $2.1 million, compared to $1.8 million for the first quarter of 2010. Operating expenses increased to $5.6 million for the first quarter of 2011 from $3.5 million for the first quarter of 2010. Neoprobe’s loss from operations for the first quarter of 2011 was $3.5 million compared to $1.7 million for the first quarter of 2010.
